Differences in the placebo response in duloxetine and venlafaxine trials
Objective Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response. Method We conducted a com...
Saved in:
Published in | Acta psychiatrica Scandinavica Vol. 137; no. 6; pp. 472 - 480 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response.
Method
We conducted a comprehensive systematic review and meta‐analysis of placebo‐controlled, double‐blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder.
Results
We included 71 studies (29 duloxetine trials and 43 venlafaxine trials; one study provided data for the duloxetine and the venlafaxine data set). The placebo effect sizes, defined as pre‐postscore change divided by baseline standard deviation, differed significantly between venlafaxine and duloxetine studies (−2.51 vs. −2.09; test for subgroup differences P = 0.028; high heterogeneity). The analysis of effect modifiers and the metaregression analyses confirmed the drug, next to baseline depression severity and publication status, as the most influential independent predictor.
Conclusion
Our analyses show a significant difference in the placebo response between venlafaxine and duloxetine trials and suggest that the investigated drug has an influence on the placebo response that is not related to baseline severity, changes over the years or other variables we included. |
---|---|
AbstractList | ObjectiveOur analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response.MethodWe conducted a comprehensive systematic review and meta‐analysis of placebo‐controlled, double‐blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder.ResultsWe included 71 studies (29 duloxetine trials and 43 venlafaxine trials; one study provided data for the duloxetine and the venlafaxine data set). The placebo effect sizes, defined as pre‐postscore change divided by baseline standard deviation, differed significantly between venlafaxine and duloxetine studies (−2.51 vs. −2.09; test for subgroup differences P = 0.028; high heterogeneity). The analysis of effect modifiers and the metaregression analyses confirmed the drug, next to baseline depression severity and publication status, as the most influential independent predictor.ConclusionOur analyses show a significant difference in the placebo response between venlafaxine and duloxetine trials and suggest that the investigated drug has an influence on the placebo response that is not related to baseline severity, changes over the years or other variables we included. Objective Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response. Method We conducted a comprehensive systematic review and meta‐analysis of placebo‐controlled, double‐blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder. Results We included 71 studies (29 duloxetine trials and 43 venlafaxine trials; one study provided data for the duloxetine and the venlafaxine data set). The placebo effect sizes, defined as pre‐postscore change divided by baseline standard deviation, differed significantly between venlafaxine and duloxetine studies (−2.51 vs. −2.09; test for subgroup differences P = 0.028; high heterogeneity). The analysis of effect modifiers and the metaregression analyses confirmed the drug, next to baseline depression severity and publication status, as the most influential independent predictor. Conclusion Our analyses show a significant difference in the placebo response between venlafaxine and duloxetine trials and suggest that the investigated drug has an influence on the placebo response that is not related to baseline severity, changes over the years or other variables we included. Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response. We conducted a comprehensive systematic review and meta-analysis of placebo-controlled, double-blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder. We included 71 studies (29 duloxetine trials and 43 venlafaxine trials; one study provided data for the duloxetine and the venlafaxine data set). The placebo effect sizes, defined as pre-postscore change divided by baseline standard deviation, differed significantly between venlafaxine and duloxetine studies (-2.51 vs. -2.09; test for subgroup differences P = 0.028; high heterogeneity). The analysis of effect modifiers and the metaregression analyses confirmed the drug, next to baseline depression severity and publication status, as the most influential independent predictor. Our analyses show a significant difference in the placebo response between venlafaxine and duloxetine trials and suggest that the investigated drug has an influence on the placebo response that is not related to baseline severity, changes over the years or other variables we included. OBJECTIVEOur analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine and venlafaxine, and at analysing a potential influence of the investigated drugs on the placebo response.METHODWe conducted a comprehensive systematic review and meta-analysis of placebo-controlled, double-blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder.RESULTSWe included 71 studies (29 duloxetine trials and 43 venlafaxine trials; one study provided data for the duloxetine and the venlafaxine data set). The placebo effect sizes, defined as pre-postscore change divided by baseline standard deviation, differed significantly between venlafaxine and duloxetine studies (-2.51 vs. -2.09; test for subgroup differences P = 0.028; high heterogeneity). The analysis of effect modifiers and the metaregression analyses confirmed the drug, next to baseline depression severity and publication status, as the most influential independent predictor.CONCLUSIONOur analyses show a significant difference in the placebo response between venlafaxine and duloxetine trials and suggest that the investigated drug has an influence on the placebo response that is not related to baseline severity, changes over the years or other variables we included. |
Author | Furukawa, T. A. Koesters, M. Breilmann, J. Becker, T. |
Author_xml | – sequence: 1 givenname: J. orcidid: 0000-0002-0591-5969 surname: Breilmann fullname: Breilmann, J. email: johanna.breilmann@uni-ulm.de organization: Bezirkskrankenhaus – sequence: 2 givenname: T. A. orcidid: 0000-0003-2159-3776 surname: Furukawa fullname: Furukawa, T. A. organization: Kyoto University Graduate School of Medicine/School of Public Health – sequence: 3 givenname: T. orcidid: 0000-0001-8179-1219 surname: Becker fullname: Becker, T. organization: Bezirkskrankenhaus – sequence: 4 givenname: M. orcidid: 0000-0001-7018-6021 surname: Koesters fullname: Koesters, M. organization: Bezirkskrankenhaus |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29603140$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kEtLw0AUhQep2Idu_AEScCNC6p1kkswsS31UKCio4C5MJncwJZ3EmUbbf-_UVhcuvJvDPXwcDmdIeqYxSMgphTH1dyVV68Y04pwekAFNAUJgLOuRAQDQMBXw2idD5xb-TSjwI9KPRAoxZTAgs-tKa7RoFLqgMsHqDYO2lgqLJrDo2sY43PplVzdrXFUGA2nK4ANNLbVcb_-VrWTtjsmh9oInex2Rl9ub5-ksnD_c3U8n81DFPKahjopUKd-Jl5SDSjjLENMiTXQBzHuRRJmIQuiECx1DJJNCUBRQ6oQilyIekYtdbmub9w7dKl9WTmFdS4NN5_IIImCCxpB59PwPumg6a3w7T7EsZjwTzFOXO0rZxjmLOm9ttZR2k1PIt_vm233z7309fLaP7Iollr_oz6AeoDvgs6px809UPpk-Pu1CvwCPGoZO |
CitedBy_id | crossref_primary_10_1097_JCP_0000000000001506 crossref_primary_10_1111_acps_13235 crossref_primary_10_1111_acps_12974 crossref_primary_10_1111_acps_13337 crossref_primary_10_1016_j_jveb_2023_06_004 crossref_primary_10_3389_fpsyt_2019_00713 crossref_primary_10_1159_000520554 crossref_primary_10_1177_00048674211068793 crossref_primary_10_1111_acps_13293 crossref_primary_10_1177_07067437221115029 crossref_primary_10_1111_acps_13000 |
Cites_doi | 10.1016/S2215-0366(16)30307-8 10.1176/appi.ajp.2012.12040474 10.1016/j.jclinepi.2010.01.005 10.1002/wps.20245 10.1192/bjp.bp.115.173906 10.1001/jamainternmed.2013.10391 10.18637/jss.v034.i12 10.1098/rstb.2010.0394 10.1097/YIC.0000000000000174 10.1136/eb-2017-102827 10.1016/j.jclinepi.2005.06.006 10.1017/S2045796011000837 10.4088/JCP.11r07485 10.1038/npp.1994.63 10.4088/JCP.v67n1111 10.1017/S1461145710000957 10.1001/jama.2009.1943 10.1001/jamapsychiatry.2015.15 10.1016/j.jclinepi.2008.10.001 10.18637/jss.v036.i03 10.1192/bjp.134.4.382 10.4088/JCP.10m06191 10.1097/01.NMD.0000061144.16176.38 10.1016/j.cct.2015.05.005 10.1097/JCP.0000000000000796 10.1001/jama.287.14.1840 10.1002/jrsm.1195 10.1016/j.jad.2009.01.029 10.1192/bjp.bp.112.120196 10.1038/npp.2011.306 10.1038/npp.2012.153 10.1017/S1461145711000666 10.1111/j.2044-8341.1959.tb00467.x 10.1037/1082-989X.7.1.105 10.1371/journal.pmed.1000097 10.1186/1471-2288-2-13 10.1136/jech.52.6.377 10.1371/journal.pone.0066844 10.1001/archgenpsychiatry.2011.2044 10.7326/0003-4819-159-2-201307160-00008 10.1016/S0006-3223(00)00846-5 10.1007/s00265-010-1029-6 10.1111/j.1755-5949.2010.00151.x |
ContentType | Journal Article |
Copyright | 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2018 John Wiley & Sons A/S, Published by John Wiley & Sons Ltd |
Copyright_xml | – notice: 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2018 John Wiley & Sons A/S, Published by John Wiley & Sons Ltd |
DBID | NPM AAYXX CITATION 7TK K9. 7X8 |
DOI | 10.1111/acps.12881 |
DatabaseName | PubMed CrossRef Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0447 |
EndPage | 480 |
ExternalDocumentID | 10_1111_acps_12881 29603140 ACPS12881 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACHQT ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN EPS ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UPT V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YF5 ZGI ZXP ZZTAW ~IA ~WT NPM AAMNL AAYXX ACRPL ACYXJ CITATION 7TK K9. 7X8 |
ID | FETCH-LOGICAL-c3831-f2b6cc6908d180c5847ee6b65fb048d12aea59b9f589f302a5b91e90df51e8a93 |
IEDL.DBID | DR2 |
ISSN | 0001-690X |
IngestDate | Wed Dec 04 05:03:57 EST 2024 Thu Oct 10 17:37:38 EDT 2024 Fri Dec 06 05:19:40 EST 2024 Wed Oct 16 00:51:04 EDT 2024 Sat Aug 24 00:59:29 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | meta-analysis placebo effect antidepressants moderator variables |
Language | English |
License | 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3831-f2b6cc6908d180c5847ee6b65fb048d12aea59b9f589f302a5b91e90df51e8a93 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-8179-1219 0000-0001-7018-6021 0000-0002-0591-5969 0000-0003-2159-3776 |
PMID | 29603140 |
PQID | 2047348794 |
PQPubID | 33508 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2020491307 proquest_journals_2047348794 crossref_primary_10_1111_acps_12881 pubmed_primary_29603140 wiley_primary_10_1111_acps_12881_ACPS12881 |
PublicationCentury | 2000 |
PublicationDate | June 2018 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: June 2018 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Aalborg |
PublicationTitle | Acta psychiatrica Scandinavica |
PublicationTitleAlternate | Acta Psychiatr Scand |
PublicationYear | 2018 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 2010; 34 2015; 14 2010; 16 2009; 62 2010; 36 2000; 47 2016; 209 2010; 303 2015; 72 2013; 203 2002; 7 2006; 59 2002; 2 2003; 191 2012; 37 2002 2012; 15 2011; 14 2009; 118 2013; 8 2018; 21 2010; 63 2012; 73 2016; 7 2011; 366 1979; 134 2016; 3 2006; 67 2017; 37 1960; 23 2013; 159 2017; 32 2002; 287 2011; 72 2015; 43 1994; 11 2011; 65 2016 2009; 6 2013; 173 2013 1998; 52 2012; 69 2013; 170 2012; 21 2014; 222 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_42_1 e_1_2_9_40_1 e_1_2_9_45_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Kirsch I (e_1_2_9_22_1) 2014; 222 Burnham KP (e_1_2_9_20_1) 2002 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_29_1 |
References_xml | – volume: 23 start-page: 56 year: 1960 end-page: 62 article-title: A rating scale for depression publication-title: J Neurol Neurosurg Psychiatry – volume: 47 start-page: 736 year: 2000 end-page: 744 article-title: Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression publication-title: Biol Psychiatry – volume: 366 start-page: 1879 year: 2011 end-page: 1888 article-title: Lessons learned from placebo groups in antidepressant trials publication-title: Philos Trans R Soc Lond B Biol Sci – volume: 59 start-page: 7 year: 2006 end-page: 10 article-title: Imputing missing standard deviations in meta‐analyses can provide accurate results publication-title: J Clin Epidemiol – volume: 14 start-page: 405 year: 2011 end-page: 412 article-title: Efficacy of antidepressants: a re‐analysis and re‐interpretation of the Kirsch data publication-title: Int J Neuropsychopharmacol – volume: 173 start-page: 1941 year: 2013 end-page: 1951 article-title: Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis publication-title: JAMA Intern Med – volume: 2 start-page: 13 year: 2002 article-title: The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? publication-title: BMC Med Res Methodol – volume: 287 start-page: 1840 year: 2002 end-page: 1847 article-title: Placebo response in studies of major depression: variable, substantial, and growing publication-title: JAMA – volume: 15 start-page: 289 year: 2012 end-page: 296 article-title: Does the frequency of follow‐up assessments affect clinical trial outcome? A meta‐analysis and meta‐regression of placebo‐controlled randomized trials publication-title: Int J Neuropsychopharmacol – volume: 16 start-page: 217 year: 2010 end-page: 226 article-title: Why has the antidepressant‐placebo difference in antidepressant clinical trials diminished over the past three decades? publication-title: CNS Neurosci Ther – volume: 7 start-page: 105 year: 2002 end-page: 125 article-title: Combining effect size estimates in meta‐analysis with repeated measures and independent‐groups designs publication-title: Psychol Methods – volume: 32 start-page: 184 year: 2017 end-page: 194 article-title: Antidepressant effect in older depressed patients: the lessons of two agomelatine trials publication-title: Int Clin Psychopharmacol – volume: 72 start-page: 500 year: 2015 end-page: 510 article-title: Reporting bias in clinical trials investigating the efficacy of second‐generation antidepressants in the treatment of anxiety disorders: a report of 2 meta‐analyses publication-title: JAMA Psychiatry – volume: 209 start-page: 427 year: 2016 end-page: 428 article-title: Initial depression severity and response to antidepressants v. placebo: patient‐level data analysis from 34 randomised controlled trials publication-title: Br J Psychiatry – volume: 43 start-page: 60 year: 2015 end-page: 62 article-title: Empirically derived criteria cast doubt on the clinical significance of antidepressant‐placebo differences publication-title: Contemp Clin Trials – volume: 67 start-page: 1741 year: 2006 end-page: 1746 article-title: Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo‐controlled studies of escitalopram publication-title: J Clin Psychiatry – volume: 3 start-page: 1059 year: 2016 end-page: 1066 article-title: Placebo response rates in antidepressant trials: a systematic review of published and unpublished double‐blind randomised controlled studies publication-title: Lancet Psychiatry – volume: 191 start-page: 211 year: 2003 end-page: 218 article-title: Placebo response and antidepressant clinical trial outcome publication-title: J Nerv Ment Dis – volume: 73 start-page: 1300 year: 2012 end-page: 1306 article-title: Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta‐analysis publication-title: J Clin Psychiatry – volume: 11 start-page: 33 year: 1994 end-page: 43 article-title: Does a placebo run‐in or a placebo treatment cell affect the efficacy of antidepressant medications? publication-title: Neuropsychopharmacology – volume: 21 start-page: 1 year: 2018 end-page: 3 article-title: Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long‐lasting controversy publication-title: Evid Based Ment Health – year: 2016 – volume: 72 start-page: 464 year: 2011 end-page: 472 article-title: Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US food and drug administration in support of new drug applications publication-title: J Clin Psychiatry – volume: 203 start-page: 179 year: 2013 end-page: 187 article-title: Agomelatine efficacy and acceptability revisited: systematic review and meta‐analysis of published and unpublished randomised trials publication-title: Br J Psychiatry – volume: 52 start-page: 377 year: 1998 end-page: 384 article-title: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non‐randomised studies of health care interventions publication-title: J Epidemiol Community Health – volume: 14 start-page: 304 year: 2015 end-page: 306 article-title: Factors contributing to the increasing placebo response in antidepressant trials publication-title: World Psychiatry – volume: 37 start-page: 648 year: 2017 end-page: 650 article-title: Antidepressant trials: are the diminishing effect sizes of efficacy trials avoidable? publication-title: J Clin Psychopharmacol – volume: 69 start-page: 572 year: 2012 end-page: 579 article-title: Benefits from antidepressants: synthesis of 6‐week patient‐level outcomes from double‐blind placebo‐controlled randomized trials of fluoxetine and venlafaxine publication-title: Arch Gen Psychiatry – volume: 134 start-page: 382 year: 1979 end-page: 389 article-title: A new depression scale designed to be sensitive to change publication-title: Br J Psychiatry – volume: 222 start-page: 128 year: 2014 end-page: 134 article-title: Antidepressants and the Placebo Effect publication-title: Z Psychol – volume: 303 start-page: 47 year: 2010 end-page: 53 article-title: Antidepressant drug effects and depression severity: a patient‐level meta‐analysis publication-title: JAMA – volume: 62 start-page: 857 year: 2009 end-page: 864 article-title: A case study of multiple‐treatments meta‐analysis demonstrates that covariates should be considered publication-title: J Clin Epidemiol – year: 2002 – volume: 34 start-page: 1 year: 2010 end-page: 29 article-title: glmulti: an r package for easy automated model selection with (generalized) linear models publication-title: J Stat Softw – volume: 37 start-page: 851 year: 2012 end-page: 864 article-title: Randomized, placebo‐controlled trials of antidepressants for acute major depression: thirty‐year meta‐analytic review publication-title: Neuropsychopharmacology – volume: 8 start-page: e66844 year: 2013 article-title: Systematic review of the empirical evidence of study publication bias and outcome reporting bias ‐ an updated review publication-title: PLoS ONE – volume: 118 start-page: 1 year: 2009 end-page: 8 article-title: Meta‐analysis of the placebo response in antidepressant trials publication-title: J Affect Disord – volume: 63 start-page: 587 year: 2010 end-page: 588 article-title: Study designs to detect sponsorship and other biases in systematic reviews publication-title: J Clin Epidemiol – volume: 65 start-page: 23 year: 2011 end-page: 35 article-title: AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons publication-title: Behav Ecol Sociobiol – volume: 159 start-page: 130 year: 2013 end-page: 137 article-title: Conceptual and technical challenges in network meta‐analysis publication-title: Ann Intern Med – volume: 6 start-page: e1000097 year: 2009 article-title: Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement publication-title: PLoS Med – volume: 37 start-page: 2830 year: 2012 end-page: 2836 article-title: A meta‐analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites publication-title: Neuropsychopharmacology – volume: 21 start-page: 151 year: 2012 end-page: 153 article-title: What is a multiple treatments meta‐analysis? publication-title: Epidemiol Psychiatr Sci – volume: 170 start-page: 723 year: 2013 end-page: 733 article-title: A model of placebo response in antidepressant clinical trials publication-title: Am J Psychiatry – volume: 7 start-page: 236 year: 2016 end-page: 263 article-title: GetReal in network meta‐analysis: a review of the methodology publication-title: Res Synth Methods – year: 2013 – volume: 36 start-page: 1 year: 2010 end-page: 48 article-title: Conducting meta‐analyses in R with the metafor package publication-title: J Stat Soft – ident: e_1_2_9_9_1 doi: 10.1016/S2215-0366(16)30307-8 – ident: e_1_2_9_43_1 doi: 10.1176/appi.ajp.2012.12040474 – ident: e_1_2_9_25_1 doi: 10.1016/j.jclinepi.2010.01.005 – ident: e_1_2_9_33_1 doi: 10.1002/wps.20245 – ident: e_1_2_9_34_1 doi: 10.1192/bjp.bp.115.173906 – ident: e_1_2_9_46_1 doi: 10.1001/jamainternmed.2013.10391 – ident: e_1_2_9_29_1 doi: 10.18637/jss.v034.i12 – ident: e_1_2_9_32_1 doi: 10.1098/rstb.2010.0394 – ident: e_1_2_9_48_1 – ident: e_1_2_9_37_1 doi: 10.1097/YIC.0000000000000174 – ident: e_1_2_9_47_1 doi: 10.1136/eb-2017-102827 – ident: e_1_2_9_19_1 doi: 10.1016/j.jclinepi.2005.06.006 – ident: e_1_2_9_2_1 doi: 10.1017/S2045796011000837 – ident: e_1_2_9_42_1 doi: 10.4088/JCP.11r07485 – ident: e_1_2_9_44_1 doi: 10.1038/npp.1994.63 – ident: e_1_2_9_28_1 doi: 10.4088/JCP.v67n1111 – ident: e_1_2_9_31_1 doi: 10.1017/S1461145710000957 – ident: e_1_2_9_35_1 doi: 10.1001/jama.2009.1943 – ident: e_1_2_9_40_1 doi: 10.1001/jamapsychiatry.2015.15 – ident: e_1_2_9_6_1 doi: 10.1016/j.jclinepi.2008.10.001 – ident: e_1_2_9_30_1 doi: 10.18637/jss.v036.i03 – ident: e_1_2_9_16_1 doi: 10.1192/bjp.134.4.382 – ident: e_1_2_9_11_1 doi: 10.4088/JCP.10m06191 – ident: e_1_2_9_41_1 doi: 10.1097/01.NMD.0000061144.16176.38 – ident: e_1_2_9_38_1 doi: 10.1016/j.cct.2015.05.005 – ident: e_1_2_9_45_1 doi: 10.1097/JCP.0000000000000796 – ident: e_1_2_9_13_1 – ident: e_1_2_9_23_1 doi: 10.1001/jama.287.14.1840 – ident: e_1_2_9_4_1 doi: 10.1002/jrsm.1195 – ident: e_1_2_9_8_1 doi: 10.1016/j.jad.2009.01.029 – volume-title: Model Selection and Multimodel Inference: a Practical Information‐Theoretic Approach year: 2002 ident: e_1_2_9_20_1 contributor: fullname: Burnham KP – ident: e_1_2_9_24_1 doi: 10.1192/bjp.bp.112.120196 – ident: e_1_2_9_12_1 doi: 10.1038/npp.2011.306 – ident: e_1_2_9_7_1 doi: 10.1038/npp.2012.153 – ident: e_1_2_9_27_1 doi: 10.1017/S1461145711000666 – ident: e_1_2_9_15_1 doi: 10.1111/j.2044-8341.1959.tb00467.x – ident: e_1_2_9_18_1 doi: 10.1037/1082-989X.7.1.105 – ident: e_1_2_9_14_1 doi: 10.1371/journal.pmed.1000097 – ident: e_1_2_9_5_1 doi: 10.1186/1471-2288-2-13 – ident: e_1_2_9_17_1 doi: 10.1136/jech.52.6.377 – ident: e_1_2_9_39_1 doi: 10.1371/journal.pone.0066844 – ident: e_1_2_9_36_1 doi: 10.1001/archgenpsychiatry.2011.2044 – ident: e_1_2_9_3_1 doi: 10.7326/0003-4819-159-2-201307160-00008 – volume: 222 start-page: 128 year: 2014 ident: e_1_2_9_22_1 article-title: Antidepressants and the Placebo Effect publication-title: Z Psychol contributor: fullname: Kirsch I – ident: e_1_2_9_26_1 doi: 10.1016/S0006-3223(00)00846-5 – ident: e_1_2_9_21_1 doi: 10.1007/s00265-010-1029-6 – ident: e_1_2_9_10_1 doi: 10.1111/j.1755-5949.2010.00151.x |
SSID | ssj0005108 |
Score | 2.3613338 |
Snippet | Objective
Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely... Our analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely duloxetine... ObjectiveOur analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely... OBJECTIVEOur analysis aimed at comparing the placebo effect sizes from randomized controlled trials (RCTs) of two widely prescribed antidepressants, namely... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 472 |
SubjectTerms | Antidepressants Duloxetine Mental depression Meta-analysis moderator variables Placebo effect Placebos Venlafaxine |
Title | Differences in the placebo response in duloxetine and venlafaxine trials |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Facps.12881 https://www.ncbi.nlm.nih.gov/pubmed/29603140 https://www.proquest.com/docview/2047348794 https://search.proquest.com/docview/2020491307 |
Volume | 137 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB5EQXzxPuJFRJ-ElGS7m2bBl2otRVDEA_oiYTbZBbGkYlsQf72zm6ReIOhbjg2b7OzMfJO5AI4U44Y0KwYcIxVYjRWQEtYBE4ixaUmRc5uNfHkV9-75RV_0Z-CkzoUp60NMf7hZznDy2jI4qtEnJsfsedQg6eryrqNmy8bzdW4-akfRZivFMNnLZAL2q9qkNozn49Gv2ugHxPyKWJ3K6S7BQ_2yZaTJU2MyVo3s7Vsdx_9-zTIsVljUb5ebZwVmdLEK85eVt30Nep2qewrJEv-x8Akr-i6GSw39lzK2Vtvr-WQwfLWp09rHIvdJfA7Q4Ks9d01BRutw3z2_O-sFVeeFICOLNQoMU3GW0aoleZSEmXWlah2rWBhFHJ9HDDUKqaQRiTTNkKFQMtIyzI2IdIKyuQGzxbDQW-Aja7GYGRUbhjxPmCJIr3nOmwkawULlwWFNgfS5LLCR1oaJXZTULYoHuzVx0orJRikLua3NQxLFg4PpbWIP6_PAQg8ndgyNkqSoWx5slkSdTsOkbbHNQw-OHWl-mT9tn13fuqPtvwzegQUCWEkZWrYLs-OXid4jEDNW-zDXPu2cdvfdpn0HV4btaQ |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB5EQX3xPuIZ0SchJdnuptnH4kE9KuIBfQu7yS6IJRXbQvHXO7NJ6wWCvuXYsGRnZ-abnQvgSDNuUbOqgKtIB6SxAlTCJmBCqdg2pMg5ZSO3b-LWI7_siE4Vm0O5MGV9iMmBG3GGk9fE4HQg_YnLVfbSr6F4pcTrGeT3iCK6Tu8-qkfhdisFMVrMaAR2quqkFMjz8e1XffQDZH7FrE7pnC-WnVX7rlYhxZo814YDXcvevlVy_Pf_LMFCBUf9Zrl_lmHKFCsw264c7qvQOq0aqKA48Z8KH-Gi78K4dM9_LcNrDT3Ph93eiLKnja-K3EcJ2lVWjeje9QXpr8Hj-dnDSSuomi8EGRqtUWCZjrMMly3JoyTMyJtqTKxjYTUyfR4xZZSQWlqRSFsPmRJaRkaGuRWRSZSsr8N00SvMJviKNVjMrI4tUzxPmEZUb3jO64mygoXag8MxCdKXssZGOrZNaFFStyge7Iypk1Z81k9ZyKk8DwoVDw4mr5FDyO2hCtMb0hgcJVFXNzzYKKk6mYZJ6rLNQw-OHW1-mT9tntzeu6utvwzeh7nWQ_s6vb64udqGecRbSRlptgPTg9eh2UVMM9B7bue-A8Jx8Bg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rS8MwED9EYfjF96M6taKfhI42S7oG_CLOMZ8MdbAvUpImAVG64TYY_vVe-phOQdBvfaSkzeXuftd7ARxLQg1qVuFREUjPaiwPlbD2CBMiNA3OFLXZyLd3YbtLr3qsNwenZS5MXh9i-sPNckYmry2DD5T5wuQiGQxrKF1t3vUCDQm3lfOb95_Fo3C35XIYDWa0AXtFcVIbx_P57Kw6-oExZyFrpnNay_BUvm0eavJSG49kLXn_Vsjxv5-zAksFGHXP8t2zCnM6XYPKbeFuX4d2s2ifgsLEfU5dBItuFsQl--5bHlyr7XU1fu1PbO60dkWqXJSfr8KIiT3PuoIMN6Dbung8b3tF6wUvQZM18AyRYZLgqkUqiPzE-lK1DmXIjESWVwERWjAuuWERN3WfCCZ5oLmvDAt0JHh9E-bTfqq3wRWkQUJiZGiIoCoiEjG9porWI2EY8aUDRyUF4kFeYSMuLRO7KHG2KA5US-LEBZcNY-JTW5wHRYoDh9PbyB_W6SFS3R_bMTiKo6ZuOLCVE3U6DeG2xzb1HTjJSPPL_PHZeechO9r5y-ADqHSarfjm8u56FxYRbEV5mFkV5kdvY72HgGYk97N9-wEC6e7H |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differences+in+the+placebo+response+in+duloxetine+and+venlafaxine+trials&rft.jtitle=Acta+psychiatrica+Scandinavica&rft.au=Breilmann%2C+J.&rft.au=Furukawa%2C+T.+A.&rft.au=Becker%2C+T.&rft.au=Koesters%2C+M.&rft.date=2018-06-01&rft.issn=0001-690X&rft.eissn=1600-0447&rft.volume=137&rft.issue=6&rft.spage=472&rft.epage=480&rft_id=info:doi/10.1111%2Facps.12881&rft.externalDBID=10.1111%252Facps.12881&rft.externalDocID=ACPS12881 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-690X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-690X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-690X&client=summon |